scholarly journals Isolated Recurrence of Granulocytic Sarcoma of the Brain: Successful Treatment with Surgical Resection, Intrathecal Injection, Irradiation and Prophylactic Systemic Chemotherapy

1999 ◽  
Vol 29 (4) ◽  
pp. 214-218 ◽  
Author(s):  
K. Yamamoto ◽  
H. Hamaguchi ◽  
K. Nagata ◽  
M. Hara ◽  
O. Tone ◽  
...  
Neurosurgery ◽  
2014 ◽  
Vol 74 (suppl_1) ◽  
pp. S74-S82 ◽  
Author(s):  
R. Webster Crowley ◽  
Andrew F. Ducruet ◽  
Cameron G. McDougall ◽  
Felipe C. Albuquerque

Abstract Arteriovenous malformations (AVMs) of the brain represent unique challenges for treating physicians. Although these lesions have traditionally been treated with surgical resection alone, advancements in endovascular and radiosurgical therapies have greatly expanded the treatment options for patients harboring brain AVMs. Perhaps no subspecialty within neurosurgery has seen as many advancements over a relatively short period of time as the endovascular field. A number of these endovascular innovations have been designed primarily for cerebral AVMs, and even those advancements that are not particular to AVMs have resulted in substantial changes to the way cerebral AVMs are treated. These advancements have enabled the embolization of cerebral AVMs to be performed either as a stand-alone treatment, or in conjunction with surgery or radiosurgery. Perhaps nothing has impacted the treatment of brain AVMs as substantially as the development of liquid embolics, most notably Onyx and n-butyl cyanoacrylate. However, of near-equal impact has been the innovations seen in the catheters that help deliver the liquid embolics to the AVMs. These developments include flow-directed catheters, balloon-tipped catheters, detachable-tipped catheters, and distal access catheters. This article aims to review some of the more substantial advancements in the endovascular treatment of brain AVMs and to discuss the literature surrounding the expanding indications for endovascular treatment of these lesions.


2007 ◽  
Vol 10 (1) ◽  
pp. 58-62 ◽  
Author(s):  
Akihiro Nakajo ◽  
Shoji Natsugoe ◽  
Shuichi Hokita ◽  
Sumiya Ishigami ◽  
Hiroyuki Takatori ◽  
...  

2007 ◽  
Vol 106 (6) ◽  
pp. 1213-1219 ◽  
Author(s):  
Ken-ichiro Hayashida ◽  
Renée Parker ◽  
James C. Eisenach

Background Gabapentin administration into the brain of mice reduces nerve injury-induced hypersensitivity and is blocked by intrathecal atropine and enhanced by intrathecal neostigmine. The authors tested the relevance of these findings to oral therapy by examining the efficacy of oral gabapentin to reduce hypersensitivity after nerve injury in rats and its interaction with the clinically used cholinesterase inhibitor, donepezil. Methods Male rats with hypersensitivity after spinal nerve ligation received gabapentin orally, intrathecally, and intracerebroventricularly with or without intrathecal atropine, and withdrawal threshold to paw pressure was determined. The effects of oral gabapentin and donepezil alone and in combination on withdrawal threshold were determined in an isobolographic design. Results Gabapentin reduced hypersensitivity to paw pressure by all routes of administration, and was more potent and with a quicker onset after intracerebroventricular than intrathecal injection. Intrathecal atropine reversed the effect of intracerebroventricular and oral gabapentin. Oral gabapentin and donepezil interacted in a strongly synergistic manner, with an observed efficacy at one tenth the predicted dose of an additive interaction. The gabapentin-donepezil combination was reversed by intrathecal atropine. Conclusions Although gabapentin may relieve neuropathic pain by actions at many sites, these results suggest that its actions in the brain to cause spinal cholinergic activation predominate after oral administration. Side effects, particularly nausea, cannot be accurately determined on rats. Nevertheless, oral donepezil is well tolerated by patients in the treatment of Alzheimer dementia, and the current study provides the rationale for clinical study of combination of gabapentin and donepezil to treat neuropathic pain.


Author(s):  
James Felker ◽  
Brianna Patterson ◽  
David Wrubel ◽  
Anna Janss

Abstract Prolactinomas are a rare subset of brain tumors in pediatrics. We report a child with a prolactin secreting macroadenoma which was refractory to initial treatment with a dopamine antagonist. Given the location of her tumor she was ineligible for surgical resection. Temozolomide (200 mg/m


1990 ◽  
Vol 37 (5) ◽  
pp. 753-762
Author(s):  
SETSUKO NAKAMURA ◽  
NOBUAKI KUZUYA ◽  
YOSHINOBU KOIDE ◽  
MASAKO MATSUMARA ◽  
YASUKO WATANABE ◽  
...  

1994 ◽  
Vol 3 (1) ◽  
pp. 10-17 ◽  
Author(s):  
Kazuyoshi Korosue ◽  
Yoshie Hara ◽  
Norihiko Tamaki ◽  
Roberto C Hiros

2019 ◽  
Vol 12 (1) ◽  
pp. bcr-2018-226284 ◽  
Author(s):  
Rachna Meel ◽  
Arjun Desai ◽  
Nripen Gaur ◽  
Sameer Bakhshi

A 19-year-old woman presented to the outpatient department with occasional ocular pain and redness and a perilimbal mass, which she noticed 5 months ago in her left eye. She had no systemic complaints. Ultrasound biomicroscopy of the mass showed a hypoechoic lesion with uniform reflectivity. The patient underwent an excision biopsy and a histopathological analysis revealed features suggestive of a granulocytic sarcoma/myeloid sarcoma. Further haematopathological evaluation confirmed concurrent acute myeloid (myelomonocytic) leukaemia French American British classification M4. There was complete remission of the ocular surface lesion and leukaemia with systemic chemotherapy. At the last follow-up of 18 months post-treatment the patient is free of disease.


Sarcoma ◽  
2011 ◽  
Vol 2011 ◽  
pp. 1-8 ◽  
Author(s):  
Anne C. Onishi ◽  
Alexander M. Hincker ◽  
Francis Y. Lee

Chondrosarcoma, a primary malignancy of bone, has eluded successful treatment with modern chemotherapeutic and radiation regimens. To date, surgical resection of these tumors remains the only curative treatment offered to patients with this diagnosis. Understanding and exploring the nature of chemotherapy and radiation resistance in chondrosarcoma could lead to new molecular targets and more directed therapy for these notoriously difficult-to-treat tumors. Here we review the most current hypotheses regarding the molecular mechanisms mediating chemotherapy and radiation resistance and the future direction of chondrosarcoma therapy research.


2001 ◽  
Vol 46 (4) ◽  
pp. 225-226 ◽  
Author(s):  
Sang-Ahm Lee ◽  
Ji Yeon Ryu ◽  
Soon Keum Lee ◽  
Joong-Koo Kang

Sign in / Sign up

Export Citation Format

Share Document